爵士制药 JAZZ 深 沪
等待开盘 02-12 09:30:00 美东时间
164.77
-0.850
-0.51%
华盛通- 最 高175.80
- 今 开165.08
- 成交量 6.85万股
- 最 低 156.95
- 昨 收 165.62
- 总市值 1028.87万
- 52周最高 182.99
- 市盈率 静 --
- 换手率 109.70%
- 52周最低 95.49
- 委 比 90.07%
- 总股本 6.24万
- 历史最高 194.73
- 量 比 0.56
- 振 幅 11.38%
- 历史最低 1.10
- 每 手 1
- 风险率 22.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $235
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $210 to $235.
01-12 17:46
晚报| 美批准英伟达向中国销售芯片！AI产业链全线爆发！中央城市工作会议：加快构建房地产发展新模式！7月15日影响重磅消息汇总
（来源：京城夜读） 收盘总结 创业板指放量大涨1.73%、沪指险守3500点！两市下跌个股超4000只 AI产业链全线爆发。三大指数全天表现分化，收盘涨跌不一...
2025-07-15 19:43
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-11 00:16
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $140 price target.
2024-09-09 23:43
Jazz Pharmaceuticals Highlights Zanidatamab and Zepzelca Cancer Trials at ESMO Congress
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024,
2024-09-09 20:00
Jazz Pharmaceuticals Launches $850 Million Senior Notes Offering, $150 Million Share Buyback
08:03 AM EDT, 09/03/2024 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) said Tuesday that its subsidiary Jazz Investments I plans to offer $850 million of exchangeable senior notes due 2030 in a private offering. The company said initial purchasers of the notes will be granted a 13-day option to buy ...
2024-09-03 20:03
Jazz Intends To Offer $850M Of Exchangeable Senior Notes Due 2030 In Private Offering; Plans Concurrent Ordinary Share Repurchases Up To $150M Of Its Ordinary Shares
Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to approximately $350 million of the term loans outstanding under the credit agreement and the remainder for general corporate purposes.
2024-09-03 19:02
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) and Hikma Pharmaceuticals Plc (OTC:HKMPF) (OTC:HKMPY) are set to face allegations that they conspired to delay the release of a generic version of Jazz’s blockbuster narcolepsy drug, Xyrem, resulting in higher prices for health plans. Narcolepsy is a rare, chro...
2024-08-29 01:37
Avadel Pharma Shares Fall After Split Decision in Legal Fight Over Narcolepsy Drug
01:01 PM EDT, 08/28/2024 (MT Newswires) -- Avadel Pharmaceuticals (AVDL) shares declined Wednesday after scoring a partial victory in a legal fight with Jazz Pharmaceuticals (JAZZ) over Avadel's bid to commercialize its Lumryz medication for the treatment of excessive daytime sleepiness in adults wi...
2024-08-29 01:01
